Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases
Led by new investor Petrichor, with participation from new and existing investors
Lead product candidate, QTORIN™ rapamycin, in late-stage clinical development for serious, rare genetic skin diseases with no FDA-approved therapies
Top-line data expected in mid-2023 from Phase 3 pivotal study evaluating QTORIN™ rapamycin in Pachyonychia Congenita
Comments are closed.